CytomX Therapeutics (CTMX) Tax Provisions (2015 - 2026)
CytomX Therapeutics' (CTMX) quarterly Tax Provisions came in at $59000.0 in Q1 2026, down 4.84% YoY from $62000.0 in Q1 2025, and up 101.56% on a QoQ basis from -$3.8 million in Q4 2025.
CytomX Therapeutics (CTMX) Tax Provisions (2015 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 10 years of Tax Provisions data on file, last reported at $59000.0 in Q1 2026.
- Quarterly Tax Provisions fell 4.84% year-over-year to $59000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 million (down 1626.27% YoY) and the FY2025 annual result came in at -$3.6 million, down 1706.25% from the prior year.
- Tax Provisions grew to $59000.0 in Q1 2026, from -$3.8 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $2.8 million in Q3 2023 to a low of -$3.8 million in Q4 2025.
- A 4-year average of $52272.7 and a median of $61000.0 in 2024 frame the typical range for Tax Provisions.
- The widest YoY moves for Tax Provisions: up 26.53% in 2025, down 6200.0% in 2025.
- Tracing CTMX's Tax Provisions over 4 years: stood at $1.1 million in 2023, then sank by 94.2% to $62000.0 in 2024, then sank by 6200.0% to -$3.8 million in 2025, then jumped by 101.56% to $59000.0 in 2026.
- The last three Tax Provisions figures came in at $59000.0 (Q1 2026), -$3.8 million (Q4 2025), and $58000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 60,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60,000.00 |
| Mar 31, 2026 | 59,000.00 |
| Dec 31, 2025 | -3.78 Mn |
| Sep 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 2.82 Mn |
| Dec 31, 2020 | 11,000.00 |
| Mar 31, 2020 | -13.91 Mn |
| Dec 31, 2019 | -384,000.00 |
| Mar 31, 2019 | -6,000.00 |
| Dec 31, 2018 | 8.91 Mn |
| Sep 30, 2018 | 2.50 Mn |
| Jun 30, 2018 | 1.79 Mn |
| Mar 31, 2018 | 1.10 Mn |